Aims and Methods: This study investigated the effects of conjugated linoleic acid (CLA) on the body weight, fat deposition and the expression of stearoyl coenzyme A desaturase 1 (SCD1) in the livers of male ICR mice that were fed with either beef tallow (BT) or fish oil (FO) supplemented with CLA. Mice weighing 25–30 g were divided into four groups, BT and BT supplemented with 0.5% CLA (BTC), FO and FO supplemented with 0.5% CLA (FOC). Each group consisted of 8 mice, and they were fed the experimental diets for 4 weeks. The experimental diets were composed of 59.18% carbohydrates, 19.73% proteins and 21.09% fat in terms of their contributions to total calories, and other nutrients were identical. CLA was added to the diets of the CLA supplementation groups at 0.5% (w/w). The measurement of triglyceride (TG) was done by using a kit. Fatty acid compositions were analyzed in both the plasma and the liver using a gas chromatograph. The levels of SCD1 expression were analyzed by RT-PCR in the liver. Results: No significant difference was found in the levels of food intake, body weight and food efficiency among experimental groups. However, the levels of both epididymal and visceral fat weight were significantly lower in the CLA-supplemented groups, BTC and FOC (p < 0.05). The level of the triglyceride concentration was also significantly lower in the CLA-supplemented groups (p < 0.05). The levels of the liver SCD1 gene expression were also higher in the CLA-supplemented groups. However, significant inhibition of conversion from C16:0 to C16:1 was found in both fatty acid compositions of the liver (p < 0.05). Conclusion: Addition of 0.5% CLA did not inhibit the liver SCD1 gene expression; however, it showed decreasing effects on the fat pad weight, the concentration of TG and on fatty acid composition, leading to a decrease in the fat depositions. Such effects were clearer when CLA was supplemented to BT rather than FO.

Keywords:
Conjugated linoleic acid, Body weight, Fat depots, Triglyceride, Fatty acid compositions, Stearoyl coenzyme A desaturase 1
This content is only available via PDF.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.